Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
about
Targeting JAK2 in the therapy of myeloproliferative neoplasmsMASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathwayAKT is a therapeutic target in myeloproliferative neoplasmsBim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signalingThe dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients.The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis.Molecular classification of myeloproliferative neoplasms-pros and cons.JAK2 inhibitors for myeloproliferative neoplasms: what is next?JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.Aberrant expression of signaling proteins in essential thrombocythemia.PI3K-Akt Signal Transduction Molecules Maybe Involved in Downregulation of Erythroblasts Apoptosis and Perifosine Increased Its Apoptosis in Chronic Mountain Sickness.Implication of MAPK1/MAPK3 signalling pathway in t(8;9)(p22;24)/PCM1-JAK2 myelodysplastic/myeloproliferative neoplasms.Deregulated expression of A1, Bcl-2, Bcl-xL, and Mcl-1 antiapoptotic proteins and Bid, Bad, and Bax proapoptotic genes in polycythemia vera patients
P2860
Q26860796-6CDF4F65-C4D7-4A3D-9C86-D7ADB8A75A51Q30009940-7D5D02C2-1D06-421A-AF7D-9CCA1DC28480Q33623277-CB1C96CB-AD7D-4E6A-9A54-8AC54B2930A8Q33797357-7BC7E8BC-8C32-477A-BC2C-A2050A329F4BQ34378552-80B7E305-8ADF-4F54-88A0-FECBF43466C1Q35112255-BD74130D-8C9F-4A20-A10A-BAD9C2B0BDC9Q35144757-004405BD-EDEC-4B21-9AD3-C5A0B763487BQ38148982-EFBE6DB4-F07E-4B1E-88CA-06334A8A6264Q38684435-E3FBFA40-D144-4F20-8157-A9C4C5F7BF8AQ42006793-A2C8071F-13D0-45C7-AE35-3908545A7B36Q44482944-B24975E4-19CD-4EEB-8907-C3A9DC47F77DQ47098953-676ABD21-9ABD-4B29-9693-D50C7F864742Q50967796-677B4546-A746-4584-AA94-B435F37F83D5Q56787010-6468F713-C937-4D0A-BE32-D02E1E7F0D8F
P2860
Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Polycythemia vera erythroid pr ...... S and PI3K pathway activation.
@en
Polycythemia vera erythroid pr ...... S and PI3K pathway activation.
@nl
type
label
Polycythemia vera erythroid pr ...... S and PI3K pathway activation.
@en
Polycythemia vera erythroid pr ...... S and PI3K pathway activation.
@nl
prefLabel
Polycythemia vera erythroid pr ...... S and PI3K pathway activation.
@en
Polycythemia vera erythroid pr ...... S and PI3K pathway activation.
@nl
P2093
P2860
P1476
Polycythemia vera erythroid pr ...... S and PI3K pathway activation.
@en
P2093
Anil Potti
Jacob P Laubach
Kelly H Salter
Murat O Arcasoy
Xiaohong Jiang
P2860
P304
P356
10.1016/J.EXPHEM.2009.09.009
P577
2009-10-06T00:00:00Z